Skip to main content

COVID-19 Updates: Get the latest on vaccine information, in-person appointments, video visits and more. Learn More >>


Texas Medical Center

Kelsey C. Bertrand, MSc, MD


School Education Degree Year
Baylor College of Medicine Fellowship Pediatric Hematology/Oncology 2020
Cleveland Clinic Residency Pediatrics 2017
University of Queensland Medical School Doctor of Medicine 2013
University of Toronto/ The Hospital for Sick Children Masters Master of Science, Laboratory Medicine and Pathobiology 2009
University of Guelph Other Bachelor of Science, Biological Science 2007


Dr. Kelsey Bertrand completed her pediatric hematology/oncology fellowship training in 2020. Prior to her fellowship training, she completed her residency at Cleveland Clinic Children’s Hospital.

Dr. Bertrand first became interested in clinical pediatric oncology when she was in graduate school studying the epigenetics of medulloblastoma, the most common malignant brain tumor in children. She hopes that research will develop more treatment options for children with difficult-to-treat brain tumors. 

She is board certified by the American Board of Pediatrics.


Organization Name Role
American Academy of Pediatrics (AAP) Member
American Society of Clinical Oncology (ASCO) Member
American Society of Hematology (ASH) Member
American Society of Pediatric Hematology/Oncology (ASPHO) Member
Children's Oncology Group (COG) Member

Research Statement

Ependymoma is the third most common pediatric brain tumor.  Despite decades of progress in other tumor types, there are no current cytotoxic chemotherapy or targeted agents that improve patient outcomes.  My project looks to harness the power of CAR T cell therapy, while investigating epigenetic mechanisms that may affect resistance to therapy.

Dr. Bertrand’s research focuses on understanding the role epigenetics plays in high risk brain tumors, such as ependymoma and DIPG.  She is trying to uncover dependencies that can be leveraged for developing therapies in the future that will improve outcomes in patients with ependymoma and DIPG.

Selected Publications

Mack SC, Agnihotri S, Witt H, Shih DJ, Wang X, Zayne K, Barszczyk M, Ramaswamy V, Bertrand KC, Remke M, Yao Y, Ryzhova M, Massimi L, Grajkowska W, Lach B, Philips J, Gupta N, Weiss WA, Guha A,, Hawkins C, Croul S, Bader GD, Rutka JT, Zadeh G, Pfister SM, Korshunov A, Taylor MD. Spinal Myxopapillary Ependymomas Demonstrate a Warburg Phenotype. Clin Cancer Res. 2015; 21(16):3750-3758.

Faria CC, Agnihotri S, Mack SC, Golbourn BJ, Diaz RJ, Olsen S, Bryant M, Bebenek M, Wang X, Bertrand KC, Kushida M, Head R, Clark I, Dirks P, Smith CA, Taylor MD, Rutka JT. Identification of alsterpaullone as a novel small molecule inhibitor to target group 3 medulloblastoma. Oncotarget. 2015; 6(25):21718-21729.

Park JB, Agnihotri S, Golbourn B, Bertrand KC, Luck A, Sabha N, Smith CA, Byron S, Zadeh G, Croul S, Berens M, Rutka JT. Transcriptional profiling of GBM invasive genes identifies effective inhibitors of the LIM kinase-cofilin pathway. Oncotarget. 2014; 5(19):9382-95.

Mack SC, Witt H, Piro RM, Gu L, Zuyderduyn S, Stutz AM, Wang X, Gallo M, Garzia L, Zayne K, Zhang X, Ramaswamy V, Jäger N, Jones DT, Sill M, Pugh TJ, Ryzhova M, Wani KM, Shih DJ, Head R, Remke M, Bailey SD, Zichner T, Faria CC, Barszczyk M, Stark S, Seker-Cin H, Hutter S, Johann P, Bender S, Hovestadt V, Tzaridis R, Dubuc AM, Northcott PA, Peacock J, Bertrand KC, et al. Epigenetic alterations define lethal CIMP-positive ependymomas of infancy. Nature. 2014; 506(7489):445-450.

Pinkham MB, Bertrand KC, Olson S, Zarate D, Oram J, Pullar A, Foote MC. Hippocampal-sparing radiotherapy: the new standard of care for gliomas. Journal of Clinical Neuroscience. 2014; 21(1):86-90.

Mack, SC, Witt, H, Wang X, Milde, T, Yao, Y, Bertrand KC, Korshunov, A, Pfister, SM, Taylor MD. Emerging Insights into the Ependymoma Epigenome. Brain Pathology. 2013; 23(2):206-209.

Witt H, Mack SC, Ryzhova M, Bender S, Sill M, Isserlin R, Benner A, Hielscher T, Milde T, Remke M, Jones DT, Northcott PA, Garzia L, Bertrand KC, et al. Delineation of two clinically and molecularly distinct subgroups of posterior fossa ependymoma. Cancer Cell. 2011; 20(2):143-157.

Bertrand KC, Mack SC, Northcott PA, Garzia L, Dubuc A, Pfister SM, Rutka JT, Weiss WA, Taylor MD. PCDH10 is a candidate tumour suppressor gene in Medulloblastoma. Childs Nerv Syst. 2011; 27(8):1243-1249.

Shahrzad S, Bertrand K, Minhas K, Coomber BL. Induction of DNA Hypomethylation by Tumor Hypoxia. Epigenetics 2007; 2(2):119-125.

View publications on PubMed



* Texas Children's Hospital physicians' licenses and credentials are reviewed prior to practicing at any of our facilities. Sections titled From the Doctor, Professional Organizations and Publications were provided by the physician's office and were not verified by Texas Children's Hospital.